Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab

References

• Baronciani D, Angelucci E, Potschger U, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant. 2016;51(4):536–541. doi:10.1038/bmt.2015.293.
   PubMed Web of Science ®Google Scholar
• Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339–348. doi:10.1056/NEJMsa1311707.
   PubMed Web of Science ®Google Scholar
• Li C, Mathews V, Kim S, et al. Related and unrelated donor transplantation for beta-thalassemia major: results of an international survey. Blood Adv. 2019;3(17):2562–2570. doi:10.1182/bloodadvances.2019000291.
   PubMed Web of Science ®Google Scholar
• Mahadeo KM, Weinberg KI, Abdel-Azim H, et al. A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor. Biol Blood Marrow Transplant. 2015;21(3):440–444. doi:10.1016/j.bbmt.2014.11.005.
   PubMed Web of Science ®Google Scholar
• Shah AJ, Kapoor N, Crooks GM, et al. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant. 2007;13(5):584–593. doi:10.1016/j.bbmt.2007.01.076.
   PubMed Web of Science ®Google Scholar
• Mehta B, Mahadeo K, Kapoor N, Abdel-Azim H. Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease. Pediatr Transplant. 2015;19(4):408–412. doi:10.1111/petr.12471.
   PubMed Web of Science ®Google Scholar
• Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749–2756. doi:10.1182/blood-2007-03-079665.
   PubMed Web of Science ®Google Scholar
• Strocchio L, Locatelli F. Hematopoietic stem cell transplantation in thalassemia. Hematol Oncol Clin North Am. 2018;32(2):317–328. doi:10.1016/j.hoc.2017.11.011.
   PubMed Web of Science ®Google Scholar
• Kekre N, Zhang Y, Zhang MJ, et al. Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017;102(7):1291–1298. doi:10.3324/haematol.2017.164459.
   PubMed Web of Science ®Google Scholar
• Hongju Y, Lei G, Xi Z. Rabbit antithymocyte globulin versus alemtuzumab in allogeneic stem cell transplantation:a meta-analysis. Int J New Technol Res. 2016;2(5):77–81.
   Google Scholar
• Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–270. doi:10.1111/j.1365-2567.2009.03115.x.
   PubMed Web of Science ®Google Scholar
• Stauch D, Dernier A, Sarmiento Marchese E, et al. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One. 2009;4(3):e4709. doi:10.1371/journal.pone.0004709.
   PubMed Web of Science ®Google Scholar
• John TD, Friend B, Yassine K, et al. Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children’s Hospital experience. Bone Marrow Transplant. 2021;56(11):2797–2803. doi:10.1038/s41409-021-01415-6.
   PubMed Web of Science ®Google Scholar
• Ngwube A, Hayashi RJ, Murray L, et al. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015;62(7):1270–1276. doi:10.1002/pbc.25458.
   PubMed Web of Science ®Google Scholar
• Horn B, Baxter-Lowe LA, Englert L, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant. 2006;37(3):263–269. doi:10.1038/sj.bmt.1705240.
   PubMed Web of Science ®Google Scholar
• Olsson R, Remberger M, Schaffer M, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013;48(4):537–543. doi:10.1038/bmt.2012.239.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27(8):642–649. doi:10.1016/j.jtct.2021.04.007.
   PubMedGoogle Scholar
• Kenyon M, Babic A, eds. The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT [Internet]. Cham: Springer; 2018. PMID: 31314221.
   Google Scholar
• Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8(8):444–452. doi:10.1053/bbmt.2002.v8.pm12234170.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295–304. doi:10.1097/00007890-197410000-00001.
   PubMed Web of Science ®Google Scholar
• Anderson LJ. Assessment of iron overload with T2* magnetic resonance imaging. Prog Cardiovasc Dis. 2011;54(3):287–294. doi:10.1016/j.pcad.2011.07.004.
   PubMed Web of Science ®Google Scholar
• Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for beta-thalassemia major. Blood. 2011;117(5):1745–1750. doi:10.1182/blood-2010-09-306829.
   PubMed Web of Science ®Google Scholar
• Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra83. doi:10.1126/scitranslmed.3008825.
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160–1166. doi:10.1038/nm1475.
   PubMed Web of Science ®Google Scholar
• Pfeiffer T, Tzannou I, Wu M, et al. Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting. Clin Cancer Res. 2023;29(2):324–330. doi:10.1158/1078-0432.CCR-22-2415.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Merli P, Strocchio L. Transplantation for thalassemia major: alternative donors. Curr Opin Hematol. 2016;23(6):515–523. doi:10.1097/MOH.0000000000000280.
   PubMed Web of Science ®Google Scholar
• Marsh RA, Rao MB, Gefen A, et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant. 2015;21(8):1460–1470. doi:10.1016/j.bbmt.2015.04.009.
   PubMed Web of Science ®Google Scholar
• Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18(8):1265–1272. doi:10.1016/j.bbmt.2012.01.019.
   PubMed Web of Science ®Google Scholar
• Allen CE, Marsh R, Dawson P, et al. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018;132(13):1438–1451. doi:10.1182/blood-2018-01-828277.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Grossman WJ, DiPersio J, et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35(4):345–352. doi:10.1038/sj.bmt.1704795.
   PubMed Web of Science ®Google Scholar
• Marsh RA, Lane A, Mehta PA, et al. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood. 2016;127(4):503–512. doi:10.1182/blood-2015-07-659672.
   PubMed Web of Science ®Google Scholar
• Dong M, Emoto C, Fukuda T, et al. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. Br J Clin Pharmacol. 2022;88(1):248–259. doi:10.1111/bcp.14955.
   PubMed Web of Science ®Google Scholar
• Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014;49(7):913–920. doi:10.1038/bmt.2014.84.
   PubMed Web of Science ®Google Scholar
• Abdel-Azim H, Mahadeo KM, Zhao Q, et al. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. Am J Hematol. 2015;90(11):1021–1026. doi:10.1002/ajh.24141.
   PubMed Web of Science ®Google Scholar
• Andreani M, Nesci S, Lucarelli G, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 2000;25(4):401–404. doi:10.1038/sj.bmt.1702151.
   PubMed Web of Science ®Google Scholar
• Andreani M, Testi M, Battarra M, et al. Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. Blood Transfus. 2008;6(3):143–149. doi:10.2450/2008.0051-07.
   PubMed Web of Science ®Google Scholar
• Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7(12):665–673. doi:10.1053/bbmt.2001.v7.pm11787529.
   PubMed Web of Science ®Google Scholar
• Abraham A, Hsieh M, Eapen M, et al. Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2017;23(12):2178–2183. doi:10.1016/j.bbmt.2017.08.038.
   PubMed Web of Science ®Google Scholar